ClinicalTrials.gg
CompletedNCT00195715Updated Jul 12, 2011Results posted

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

A Phase 3 interventional study of Adalimumab in Crohn's Disease, sponsored by Abbott. Completed at 111 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-07-12.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
777
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
4th of 42
777 · median 143
Started
2004
with 1 other
Phase 3
22 of 42
none open now
Registered
5th of 42
by date
Lead sponsor
13 of 42
Abbott

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 4th largest by enrollment, is one of 2 that started in 2004, is one of 22 in phase 3, and was the 5th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol M04-691.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have successfully completed either the M02-404 (NCT00077779) or M04-691 (NCT00105300) protocol to be eligible for this study
  • Diagnosis of Crohn's disease
  • Willing and able to give

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of ulcerative colitis
  • Women cannot be pregnant or breastfeeding
  • Previous history of listeria infection or untreated tuberculosis
  • Previous history of cancer other than successfully treated skin cancer or carcinoma-in-situ of the cervix
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
777 participants (actual)

Interventions

  • BiologicalAdalimumab

    Adalimumab 40 mg by subcutaneous injection every other week or every week

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Achieving Clinical Remission

    Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

    Time frame: Week 156

Secondary outcomes

  1. Percentage of Subjects Achieving Clinical Remission

    Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

    Time frame: Week 48

  2. Percentage of Subjects Achieving Clinical Remission

    Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

    Time frame: Week 108

  3. Percentage of Subjects Achieving Clinical Remission

    Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

    Time frame: Week 204

  4. Percentage of Subjects Achieving Clinical Response 100 (CR-100)

    A CR-100 is a decrease from baseline in CDAI score of 100 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

    Time frame: Week 156

  5. Percentage of Subjects Achieving Clinical Response 70 (CR-70)

    A CR-70 is a decrease from baseline in CDAI score of 70 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

    Time frame: Week 156

  6. Percentage of Subjects Achieving Steroid-free Clinical Remission

    Steroid-free remission was achieved if the subject stopped taking steroids before the visit and had a Crohn's Disease Activity Index (CDAI) score of \<150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

    Time frame: Week 156

  7. Percentage of Subjects Achieving Steroid-free CR-100

    Steroid-free CR-100 was achieved if the subject stopped taking steroids before the visit and had a decrease from baseline in CDAI score of 100 or more points at that visit. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

    Time frame: Week 156

  8. Percentage of Subjects With Fistula Remission

    Fistula remission was defined as the absence of draining fistulas in subjects with fistula present at the preceding study's baseline visit.

    Time frame: Week 156

  9. Percentage of Subjects With Infection

    Time frame: Up to 262 weeks of adalimumab treatment

  10. Percentage of Subjects With Serious Infection

    Serious infections are infectious adverse events that meet at least one criterion for a serious adverse event (e.g., death, life threatening event, hospitalization) including tuberculosis (TB), bacterial sepsis, invasive fungal infections (e.g., histoplasmosis), and infections due to other opportunistic pathogens.

    Time frame: Up to 262 weeks of adalimumab treatment

  11. Percentage of Subjects With Malignancy

    Time frame: Up to 262 weeks of adalimumab treatment

  12. Percentage of Subjects With Lymphoma

    Time frame: Up to 262 weeks of adalimumab treatment

  13. Percentage of Subjects With Nonmelanoma Skin Cancer

    Time frame: Up to 262 weeks of adalimumab treatment

  14. Percentage of Subjects With Malignancy (Excluding Nonmelanoma Skin Cancer and Lymphoma)

    Time frame: Up to 262 weeks of adalimumab treatment

  15. Percentage of Subjects With Malignancy (Including Lymphoma, Excluding Nonmelanoma Skin Cancer)

    Time frame: Up to 262 weeks of adalimumab treatment

  16. Percentage of Subjects With Injection Site Reaction-related Adverse Event

    An injection site reaction is any adverse event corresponding to a preferred term beginning with "injection site" excluding injection site arthritis, injection site movement impairment, injection site photosensitivity, injection site joint effusion, injection site joint inflammation, injection site scab, injection site joint pain, or injection site laceration.

    Time frame: Up to 262 weeks of adalimumab treatment

  17. Percentage of Subjects With Opportunistic Infection (Excluding Tuberculosis)

    Time frame: Up to 262 weeks of adalimumab treatment

  18. Percentage of Subjects With Congestive Heart Failure

    Time frame: Up to 262 weeks of adalimumab treatment

  19. Percentage of Subjects With Demyelinating Disease

    Time frame: Up to 262 weeks of adalimumab treatment

  20. Percentage of Subjects With Hepatic-related Adverse Event

    Time frame: Up to 262 weeks of adalimumab treatment

  21. Percentage of Subjects With Allergic Reaction-related Adverse Event

    Time frame: Up to 262 weeks of adalimumab treatment

  22. Percentage of Subjects With Lupus-like Syndrome

    Time frame: Up to 262 weeks of adalimumab treatment

  23. Percentage of Subjects With Hematologic-related Adverse Event

    Time frame: Up to 262 weeks of adalimumab treatment

  24. Percentage of Subjects With Fatal Adverse Event

    Time frame: Up to 262 weeks of adalimumab treatment

07

Results

Posted Jan 7, 2010
Limitations and caveats
This study was stopped by the sponsor in December 2008 when the pre-specified termination criteria were met. Subjects who continued in the study through the termination date were considered as having completed the study.

Participant flow

Participant flow — Overall Study
MilestoneOpen-label Adalimumab
Started777
Completed400
Not completed377
Withdrew: Adverse event122
Withdrew: Withdrawal by subject58
Withdrew: Lost to follow-up27
Withdrew: Protocol violation13
Withdrew: Lack of efficacy93
Withdrew: Pregnancy14
Withdrew: Investigative site closure8
Withdrew: Subject moved/relocated7
Withdrew: Subject non-compliance6
Withdrew: Subject started commercial humira5
Withdrew: Subject choice3
Withdrew: Loss of response/no improvement3
Withdrew: Sponsor stopped study1
Withdrew: Administrative reasons2
Withdrew: Investigator's decision2
Withdrew: Subject wants to get pregnant4
Withdrew: Use of prohibited medication2
Withdrew: Planned surgery2
Withdrew: Increased infection rate1
Withdrew: Ineligible1
Withdrew: Colonic stricture1
Withdrew: Sponsor discontinued trial1
Withdrew: Sponsor discretion - trial ended early1

Outcome measures

SecondaryPercentage of Subjects Achieving Clinical Remission

Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Subjects Achieving Clinical Remission
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects Achieving Clinical Remission59.4
SecondaryPercentage of Subjects Achieving Clinical Remission

Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

Time frame:
Week 108
Reported as:
Number · Percentage of participants
Percentage of Subjects Achieving Clinical Remission
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects Achieving Clinical Remission68.8
PrimaryPercentage of Subjects Achieving Clinical Remission

Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

Time frame:
Week 156
Reported as:
Number · Percentage of participants
Percentage of Subjects Achieving Clinical Remission
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects Achieving Clinical Remission69.5
SecondaryPercentage of Subjects Achieving Clinical Remission

Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) score of \< 150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

Time frame:
Week 204
Reported as:
Number · Percentage of participants
Percentage of Subjects Achieving Clinical Remission
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects Achieving Clinical Remission46.7
SecondaryPercentage of Subjects Achieving Clinical Response 100 (CR-100)

A CR-100 is a decrease from baseline in CDAI score of 100 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

Time frame:
Week 156
Reported as:
Number · Percentage of participants
Percentage of Subjects Achieving Clinical Response 100 (CR-100)
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects Achieving Clinical Response 100 (CR-100)85.7
SecondaryPercentage of Subjects Achieving Clinical Response 70 (CR-70)

A CR-70 is a decrease from baseline in CDAI score of 70 or more points. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

Time frame:
Week 156
Reported as:
Number · Percentage of participants
Percentage of Subjects Achieving Clinical Response 70 (CR-70)
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects Achieving Clinical Response 70 (CR-70)91.2
SecondaryPercentage of Subjects Achieving Steroid-free Clinical Remission

Steroid-free remission was achieved if the subject stopped taking steroids before the visit and had a Crohn's Disease Activity Index (CDAI) score of \<150. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

Time frame:
Week 156
Reported as:
Number · Percentage of participants
Percentage of Subjects Achieving Steroid-free Clinical Remission
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects Achieving Steroid-free Clinical Remission63.1
SecondaryPercentage of Subjects Achieving Steroid-free CR-100

Steroid-free CR-100 was achieved if the subject stopped taking steroids before the visit and had a decrease from baseline in CDAI score of 100 or more points at that visit. The CDAI is a weighted composite score of 8 clinical factors measured over a 1-week period. A lower CDAI score indicates lesser disease severity.

Time frame:
Week 156
Reported as:
Number · Percentage of participants
Percentage of Subjects Achieving Steroid-free CR-100
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects Achieving Steroid-free CR-10074.8
SecondaryPercentage of Subjects With Fistula Remission

Fistula remission was defined as the absence of draining fistulas in subjects with fistula present at the preceding study's baseline visit.

Time frame:
Week 156
Reported as:
Number · Percentage of participants
Percentage of Subjects With Fistula Remission
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Fistula Remission55.8
SecondaryPercentage of Subjects With Infection
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Infection
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Infection80.2
SecondaryPercentage of Subjects With Serious Infection

Serious infections are infectious adverse events that meet at least one criterion for a serious adverse event (e.g., death, life threatening event, hospitalization) including tuberculosis (TB), bacterial sepsis, invasive fungal infections (e.g., histoplasmosis), and infections due to other opportunistic pathogens.

Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Serious Infection
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Serious Infection10.6
SecondaryPercentage of Subjects With Malignancy
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Malignancy
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Malignancy4.1
SecondaryPercentage of Subjects With Lymphoma
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Lymphoma
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Lymphoma0.1
SecondaryPercentage of Subjects With Nonmelanoma Skin Cancer
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Nonmelanoma Skin Cancer
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Nonmelanoma Skin Cancer1.8
SecondaryPercentage of Subjects With Malignancy (Excluding Nonmelanoma Skin Cancer and Lymphoma)
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Malignancy (Excluding Nonmelanoma Skin Cancer and Lymphoma)
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Malignancy (Excluding Nonmelanoma Skin Cancer and Lymphoma)2.3
SecondaryPercentage of Subjects With Malignancy (Including Lymphoma, Excluding Nonmelanoma Skin Cancer)
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Malignancy (Including Lymphoma, Excluding Nonmelanoma Skin Cancer)
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Malignancy (Including Lymphoma, Excluding Nonmelanoma Skin Cancer)2.4
SecondaryPercentage of Subjects With Injection Site Reaction-related Adverse Event

An injection site reaction is any adverse event corresponding to a preferred term beginning with "injection site" excluding injection site arthritis, injection site movement impairment, injection site photosensitivity, injection site joint effusion, injection site joint inflammation, injection site scab, injection site joint pain, or injection site laceration.

Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Injection Site Reaction-related Adverse Event
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Injection Site Reaction-related Adverse Event22.8
SecondaryPercentage of Subjects With Opportunistic Infection (Excluding Tuberculosis)
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Opportunistic Infection (Excluding Tuberculosis)
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Opportunistic Infection (Excluding Tuberculosis)4.9
SecondaryPercentage of Subjects With Congestive Heart Failure
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Congestive Heart Failure
Percentage of subjectsOpen-label Adalimumab
Percentage of Subjects With Congestive Heart Failure0
SecondaryPercentage of Subjects With Demyelinating Disease
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Demyelinating Disease
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Demyelinating Disease0.3
SecondaryPercentage of Subjects With Hepatic-related Adverse Event
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Hepatic-related Adverse Event
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Hepatic-related Adverse Event8.1
SecondaryPercentage of Subjects With Allergic Reaction-related Adverse Event
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Allergic Reaction-related Adverse Event
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Allergic Reaction-related Adverse Event2.7
SecondaryPercentage of Subjects With Lupus-like Syndrome
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Lupus-like Syndrome
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Lupus-like Syndrome0.4
SecondaryPercentage of Subjects With Hematologic-related Adverse Event
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Hematologic-related Adverse Event
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Hematologic-related Adverse Event1.5
SecondaryPercentage of Subjects With Fatal Adverse Event
Time frame:
Up to 262 weeks of adalimumab treatment
Reported as:
Number · Percentage of participants
Percentage of Subjects With Fatal Adverse Event
Percentage of participantsOpen-label Adalimumab
Percentage of Subjects With Fatal Adverse Event0.3

Adverse events

Collected over Up to 262 weeks of adalimumab treatment (includes adalimumab treatment in previous study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label Adalimumab—296/777 (38.1%)720/777 (92.7%)
Most frequent serious events
Showing 10 of 242
Most frequent serious events
EventOpen-label Adalimumab
Crohn's diseaseGastrointestinal disorders92/777
Small intestinal obstructionGastrointestinal disorders30/777
Anal abscessInfections and infestations15/777
Abdominal painGastrointestinal disorders11/777
Intestinal obstructionGastrointestinal disorders10/777
Anal fistulaGastrointestinal disorders8/777
PneumoniaInfections and infestations8/777
DehydrationMetabolism and nutrition disorders7/777
NauseaGastrointestinal disorders6/777
NephrolithiasisRenal and urinary disorders6/777
Most frequent other events
Showing 10 of 47
Most frequent other events
EventOpen-label Adalimumab
Crohn's diseaseGastrointestinal disorders309/777
NasopharyngitisInfections and infestations203/777
ArthralgiaMusculoskeletal and connective tissue disorders192/777
Abdominal painGastrointestinal disorders180/777
Upper respiratory tract infectionInfections and infestations150/777
NauseaGastrointestinal disorders142/777
HeadacheNervous system disorders141/777
InfluenzaInfections and infestations137/777
DiarrhoeaGastrointestinal disorders118/777
SinusitisInfections and infestations116/777

Baseline characteristics

Age Continuous
Age Continuous(years)Open-label Adalimumab
Mean38.0 ± 11.75
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Adalimumab
Female485
Male292
Region of Enrollment
Region of Enrollment(participants)Open-label Adalimumab
United States349
Australia40
Belgium66
Canada197
Denmark18
France24
Germany5
Hungary8
Italy9
Netherlands10
Poland12
South Africa20
Spain3
Sweden5
United Kingdom11
08

Study locations

111 sites
  • Site Ref # / Investigator 1894
    Huntsville, Alabama 35801, United States
  • Site Ref # / Investigator 1895
    Jacksonville, Alabama 35801, United States
  • Site Ref # / Investigator 1787
    La Jolla, California 92037, United States
  • Site Ref # / Investigator 1902
    Roseville, California 95661, United States
  • Site Ref # / Investigator 1824
    San Diego, California 92123, United States
  • Site Ref # / Investigator 1891
    San Diego, California 92123, United States
  • Site Ref # / Investigator 1860
    Englewood, Colorado 80113, United States
  • Site Ref # / Investigator 6178
    Lone Tree, Colorado 80124, United States
  • Site Ref # / Investigator 1904
    Wheat Ridge, Colorado 80033, United States
  • Site Ref # / Investigator 1858
    Bridgeport, Connecticut 06606, United States
  • Site Ref # / Investigator 1827
    Clearwater, Florida 33765, United States
  • Site Ref # / Investigator 1883
    Gainesville, Florida 32610, United States
  • Site Ref # / Investigator 1909
    Hollywood, Florida 33021, United States
  • Site Ref # / Investigator 1884
    Ormond Beach, Florida 32174, United States
  • Site Ref # / Investigator 1786
    Winter Park, Florida 32789, United States
  • Site Ref # / Investigator 1912
    Atlanta, Georgia 30342, United States
  • Site Ref # / Investigator 1878
    Arlington Heights, Illinois 60005, United States
  • Site Ref # / Investigator 2534
    Chicago, Illinois 60637, United States
  • Site Ref # / Investigator 1823
    Peoria, Illinois 61602, United States
  • Site Ref # / Investigator 1885
    Anderson, Indiana 46016, United States
  • Site Ref # / Investigator 1900
    Indianapolis, Indiana 46202, United States
  • Site Ref # / Investigator 1890
    Indianapolis, Indiana 46237, United States
  • Site Ref # / Investigator 1892
    Lexington, Kentucky 40536, United States
  • Site Ref # / Investigator 1906
    Metairie, Louisiana 70006, United States
  • Site Ref # / Investigator 1881
    Annapolis, Maryland 24101, United States
  • Site Ref # / Investigator 1829
    Chevy Chase, Maryland 20815, United States
  • Site Ref # / Investigator 1782
    Lutherville, Maryland 21093, United States
  • Site Ref # / Investigator 1887
    Silver Spring, Maryland 20901, United States
  • Site Ref # / Investigator 2602
    Worcester, Massachusetts 01610, United States
  • Site Ref # / Investigator 1773
    Plymouth, Minnesota 55446, United States
  • Site Ref # / Investigator 1856
    Rochester, Minnesota 55905, United States
  • Site Ref # / Investigator 1832
    Jackson, Mississippi 39202, United States
  • Site Ref # / Investigator 1880
    Kansas City, Missouri 64131, United States
  • Site Ref # / Investigator 1853
    Mexico, Missouri 65265, United States
  • Site Ref # / Investigator 1888
    St. Louis, Missouri 63110, United States
  • Site Ref # / Investigator 1862
    St. Louis, Missouri 63128, United States
  • Site Ref # / Investigator 1901
    Egg Harbor Township, New Jersey 08234, United States
  • Site Ref # / Investigator 1825
    Great Neck, New York 11021, United States
  • Site Ref # / Investigator 1848
    Lake Success, New York 11042, United States
  • Site Ref # / Investigator 1841
    New York, New York 10028, United States
  • Site Ref # / Investigator 1852
    Asheville, North Carolina 28801, United States
  • Site Ref # / Investigator 1882
    Charlote, North Carolina 28211, United States
  • Site Ref # / Investigator 1855
    Charlotte, North Carolina 28207, United States
  • Site Ref # / Investigator 1911
    Raleigh, North Carolina 27612, United States
  • Site Ref # / Investigator 1861
    Wilmington, North Carolina 28403, United States
  • Site Ref # / Investigator 1784
    Beachwood, Ohio 44122, United States
  • Site Ref # / Investigator 1896
    Beaver Creek, Ohio 45440, United States
  • Site Ref # / Investigator 1833
    Cincinatti, Ohio 45219, United States
  • Site Ref # / Investigator 1826
    Cleveland, Ohio 44106-5066, United States
  • Site Ref # / Investigator 1822
    Portland, Oregon 97220, United States
  • Site Ref # / Investigator 1886
    Pittsburgh, Pennsylvania 15216, United States
  • Site Ref # / Investigator 1905
    Columbia, South Carolina 29204, United States
  • Site Ref # / Investigator 1769
    Germantown, Tennessee 38138, United States
  • Site Ref # / Investigator 1907
    Nashville, Tennessee 37205, United States
  • Site Ref # / Investigator 1963
    Nashville, Tennessee 37232, United States
  • Site Ref # / Investigator 1899
    Round Rock, Texas 78681, United States
  • Site Ref # / Investigator 1903
    Salt Lake City, Utah 84107, United States
  • Site Ref # / Investigator 6180
    Charlottesville, Virginia 22911, United States
  • Site Ref # / Investigator 1783
    Danville, Virginia 24541, United States
  • Site Ref # / Investigator 1897
    Norfolk, Virginia 23502, United States
  • Site Ref # / Investigator 1850
    Spokane, Washington 99204, United States
  • Site Ref # / Investigator 1831
    Milwaukee, Wisconsin 53215, United States
  • Site Ref # / Investigator 1849
    West Bend, Wisconsin 53095, United States
  • Site Ref # / Investigator 1938
    Camperdown, New South Wales 2050, Australia
  • Site Ref # / Investigator 1940
    Bedford Park, South Australia SA 5042, Australia
  • Site Ref # / Investigator 1935
    Box Hill, Victoria 3128, Australia
  • Site Ref # / Investigator 1937
    Parkville, Victoria 3050, Australia
  • Site Ref # / Investigator 1941
    Bonheiden, 2820, Belgium
  • Site Ref # / Investigator 5189
    Brussels, 1070, Belgium
  • Site Ref # / Investigator 2535
    Leuven, 3000, Belgium
  • Site Ref # / Investigator 1868
    Calgary, Alberta T2N 4N1, Canada
  • Site Ref # / Investigator 1924
    Edmonton, Alberta T5H 2B9, Canada
  • Site Ref # / Investigator 426
    Edmonton, Alberta T6G2XB, Canada
  • Site Ref # / Investigator 1914
    Vancouver, British Columbia V5Z 1H2, Canada
  • Site Ref # / Investigator 1872
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Site Ref # / Investigator 1870
    Victoria, British Columbia V8V 3M9, Canada
  • Site Ref # / Investigator 1874
    Winnipeg, Manitoba R3A 1R9, Canada
  • Site Ref # / Investigator 1873
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Site Ref # / Investigator 1876
    Hamilton, Ontario L8N 3Z5, Canada
  • Site Ref # / Investigator 1875
    London, Ontario N6A 5K8, Canada
  • Site Ref # / Investigator 1772
    Toronto, Ontario M3N2V7, Canada
  • Site Ref # / Investigator 1865
    Toronto, Ontario M5G 1X5, Canada
  • Site Ref # / Investigator 2459
    Montreal, Quebec H3A 1A1, Canada
  • Site Ref # / Investigator 1866
    Montreal, Quebec H3G 1A4, Canada
  • Site Ref # / Investigator 1863
    Quebec City, Quebec G1S4L8, Canada
  • Site Ref # / Investigator 1952
    Arhus C, 8000, Denmark
  • Site Ref # / Investigator 1922
    Odense C, 5000, Denmark
  • Site Ref # / Investigator 1964
    Amiens, 80054, France
  • Site Ref # / Investigator 2458
    Lillie Cedex, 59037, France
  • Site Ref # / Investigator 1913
    Paris, 74575, France
  • Site Ref # / Investigator 1942
    Kiel, 24105, Germany
  • Site Ref # / Investigator 2524
    Regensburg, 93053, Germany
  • Site Ref # / Investigator 1943
    Stuttgart, D-70376, Germany
  • Site Ref # / Investigator 1944
    Budapest, H-1125, Hungary
  • Site Ref # / Investigator 1916
    Szekszard, 7100, Hungary
  • Site Ref # / Investigator 342
    Bologna, 40138, Italy
  • Site Ref # / Investigator 1945
    Rome, 00152, Italy
  • Site Ref # / Investigator 1779
    Turin, 10 158, Italy
  • Site Ref # / Investigator 1919
    Amsterdam, 1105 AZ, Netherlands
  • Site Ref # / Investigator 1946
    Heerlen, 6419 PC, Netherlands

Showing the first 100 of 111 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. Am J Clin Dermatol. 2018 Jun;19(3):437-447. doi: 10.1007/s40257-017-0341-6. PubMed 29380251 ↗
  • Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2013 Apr;7(3):213-21. doi: 10.1016/j.crohns.2012.05.015. Epub 2012 Jun 16. PubMed 22704916 ↗
  • Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009 Jul;58(7):940-8. doi: 10.1136/gut.2008.159251. Epub 2009 Feb 6. PubMed 19201775 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Mar 2006 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 20, 2005
Start
Sep 2004
Primary completionActual
Mar 2006
CompletionActual
Dec 2008
Results first posted
Jan 7, 2010
Last update
Jul 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00195715
Lead sponsor
Abbott
First posted
Sep 20, 2005
Start date
Sep 2004
Primary completion
Mar 2006
Completion
Dec 2008
Results posted
Jan 7, 2010
Last update
Jul 12, 2011

Study contacts

Anne Camez, MD
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion